Data / Drug companies / Ani Pharmaceuticals, Inc.
Ani Pharmaceuticals, Inc.: 157 products in the FDA NDC directory, labeler code 70954
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Ani Pharmaceuticals, Inc. (labeler code 70954) lists 157 products in the FDA National Drug Code Directory, covering 85 finished drugs by generic name. By type: 157 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 1, 2026.
The request: Watch Ani Pharmaceuticals, Inc. (FDA labeler code 70954): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 70954
- Products in commercial distribution
- 157
- Packages
- 257
- Finished drugs by generic name
- 85
- Prescription products
- 157
- Over the counter products
- 0
- Controlled substance products
- Schedule II 1, Schedule III 1, Schedule IV 9, Schedule V 1
- Flagged as original packager
- 146 of 146 products that carry the flag
- Started marketing in the last 12 months
- 20
- Earliest marketing start
- December 5, 2015
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 149 | 94.9% |
| New drug applications (NDA) | 8 | 5.1% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 157 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 71 | 45.2% |
| Capsule | 21 | 13.4% |
| Solution | 15 | 9.6% |
| Tablet, film coated | 15 | 9.6% |
| Suspension | 10 | 6.4% |
| Gel | 5 | 3.2% |
| Powder, for suspension | 4 | 2.5% |
| Capsule, delayed release | 3 | 1.9% |
| Tablet, for suspension | 3 | 1.9% |
| Tablet, delayed release | 2 | 1.3% |
| Granule, for solution | 1 | 0.6% |
| For suspension | 1 | 0.6% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Fosfomycin Tromethamine | 70954-040 | Granule, for solution | Generic drugs (ANDA) | October 1, 2026 |
| Macitentan | 70954-025 | Tablet, film coated | Generic drugs (ANDA) | October 1, 2026 |
| Methenamine Hippurate | 70954-959 | Tablet | New drug applications (NDA) | July 27, 2026 |
| Rifampin | 70954-893 | Capsule | Generic drugs (ANDA) | July 20, 2026 |
| Rifampin | 70954-892 | Capsule | Generic drugs (ANDA) | July 20, 2026 |
| Tapentadol Hydrochloride | 70954-801 | Solution | Generic drugs (ANDA) | July 13, 2026 |
| Mirtazapine | 70954-830 | Tablet, film coated | Generic drugs (ANDA) | May 14, 2026 |
| Mesalamine | 70954-301 | Suspension | Generic drugs (ANDA) | May 14, 2026 |
| Dapagliflozin | 70954-857 | Tablet, film coated | Generic drugs (ANDA) | May 13, 2026 |
| Dapagliflozin | 70954-856 | Tablet, film coated | Generic drugs (ANDA) | May 13, 2026 |
| Calcitriol | 70954-831 | Solution | New drug applications (NDA) | May 13, 2026 |
| Pimozide | 70954-854 | Tablet | Generic drugs (ANDA) | April 21, 2026 |
| Pimozide | 70954-853 | Tablet | Generic drugs (ANDA) | April 21, 2026 |
| Bromocriptine Mesylate | 70954-951 | Capsule | New drug applications (NDA) | April 6, 2026 |
| Sertraline Hydrochloride | 70954-900 | Capsule | Generic drugs (ANDA) | January 20, 2026 |
| Sertraline Hydrochloride | 70954-899 | Capsule | Generic drugs (ANDA) | January 20, 2026 |
| Hydroxyzine Hydrochloride | 70954-912 | Solution | Generic drugs (ANDA) | January 15, 2026 |
| Omeprazole and Sodium Bicarbonate | 70954-798 | Powder, for suspension | Generic drugs (ANDA) | January 15, 2026 |
| Omeprazole and Sodium Bicarbonate | 70954-797 | Powder, for suspension | Generic drugs (ANDA) | January 15, 2026 |
| Dexamethasone | 70954-872 | Elixir | Generic drugs (ANDA) | December 1, 2025 |
| Anagrelide | 70954-881 | Capsule | Generic drugs (ANDA) | November 6, 2025 |
| Anagrelide | 70954-879 | Capsule | Generic drugs (ANDA) | November 6, 2025 |
| Lofexidine | 70954-909 | Tablet | Generic drugs (ANDA) | October 22, 2025 |
| Clomiphene citrate | 70954-825 | Tablet | Generic drugs (ANDA) | October 17, 2025 |
| Everolimus | 70954-775 | Tablet, for suspension | Generic drugs (ANDA) | October 10, 2025 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.